Protective effect of silymarin during coronary artery bypass grafting surgery
Experimental and Clinical Cardiology, 04/13/2012
Altaei T – The anti–inflammatory and antioxidant effects of silymarin treatment provided protection against reperfusion injury and inflammation after coronary artery bypass grafting (CABG) surgery.
Of the 102 patients undergoing elective first–time CABG surgery that were recruited, 50 (49.02%) received silymarin treatment and 52 (50.9%) were controls.
Plasma cytokine levels (IL–1b, IL–6 and TNF–alpha) were measured preoperatively, 6 h and 24 h after CABG surgery.
C–reactive protein (CRP) levels, trolox equivalent antioxidant capacity (TEAC) and glutathione (GSH) and malondialdehyde (MDA) levels were analyzed.
Postoperative cytokine levels in the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels.
The area under the curve for cytokines and CRP for the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels.
Postoperative levels of TEAC and MDA in the silymarin–treated group were significantly lower than in the control group.
GSH levels were significantly elevated in the silymarin group compared with control.
No side effects or mortality were associated with the use of silymarin.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.